Search

everythinglearnresearchcommunity

for

Search:↓

Various peptides are discussed for treating male pattern baldness, with some available for topical use like GHK-Cu and Ac-KGHK, while others remain in research stages. Users are interested in experiences and sourcing these treatments.

The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.

A user's hair regrowth journey using biotin and minoxidil after initial treatments with Nizoral shampoo and Ketoconazole serum didn't work. The comments suggest the hair loss might not be male pattern baldness (MPB), but possibly Alopecia Areata, an autoimmune disorder, and recommend getting a second opinion and considering other treatments like corticosteroids.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.

Hair loss discussion involves experimenting with Sulforaphane from broccoli sprouts and possibly procyanidin b2. People seek updates on progress and if it's worth adding to treatment stack like microneedling.

The user emphasizes hydration, androgen receptors, and a 7-day ejaculation recovery period for appearance enhancement. They suggest Minoxidil, finasteride, and RU58841 for hair loss, along with a diet rich in animal fats, specific exercises, and fasting.

Copper peptides, specifically GHK-Cu, are being considered for hair regrowth, though skepticism exists due to questionable product sources. Users suggest finding reputable sources for potential benefits, while acknowledging traditional treatments like Minoxidil and Finasteride.

The post and conversation are about a user experiencing hair regrowth after using Minoxidil 5% twice daily, topical finasteride 0.05% once daily, weekly microneedling, and ketoconazole shampoo. Other users noted visible progress and shared their own treatment experiences.

A 22-year-old is using a hair loss treatment protocol including dutasteride, microneedling, 10% minoxidil, 0.1% finasteride topical, a healthy diet, and a hair multivitamin. Users discuss the effectiveness of microneedling and the intensity of the treatment.

The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.

The user is experiencing hair regrowth with oral minoxidil and dutasteride but still has fragile hairs that easily pluck out from the front center. Despite improvements, the user is concerned about the persistent fragility and shedding of these hairs.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

The conversation is about a 21-year-old male inquiring about the effectiveness of exosome therapy for hair thinning on the crown and considering whether to start Minoxidil while already on Finasteride and having had exosome injections 15 days ago.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

A user shared their 115-day progress in treating hair loss using 5% Minoxidil, topical Finasteride, biotin, microneedling, and collagen peptides. They reported visible improvement and no side effects from topical Finasteride, unlike the oral form.

Effective hair growth treatments include finasteride, minoxidil, dutasteride, and hair transplants, with additional options like microneedling, low-level laser therapy, and PRP showing some benefits. Newer treatments such as GHK-Cu peptides and ketoconazole shampoo are promising, while others like saw palmetto and biotin are less effective unless deficiencies exist.

The user noticed temple recession and front thinning. Their treatment includes microneedling, topical minoxidil and finasteride, biotin, zinc, selenium, vitamin D3, rosemary oil, and specific shampoos.

The conversation discusses managing hair loss and scalp issues, with users sharing experiences using treatments like dutasteride, finasteride, ketoconazole, sulfur soap, and topical anti-androgens. Suggestions include trying sulfur soap, scalp massages, spironolactone, and dietary changes to reduce sebum production and dandruff.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

A user experienced significant hair regrowth after 5 weeks by taking zinc, vitamin D, and biotin supplements, correcting deficiencies that were contributing to hair loss and thinning. They report a decrease in hair shedding, faster hair growth, and a thickening of their hairline without using common hair loss medications like Minoxidil or Finasteride.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

PP405 shows promise for hair growth but may need continuous use like Minoxidil. Current treatments include Minoxidil, finasteride, and dutasteride, with skepticism about a true cure due to financial interests.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

The conversation discusses using Botox to treat male pattern baldness, suggesting it may promote hair growth by increasing scalp blood flow and oxygen, reducing dihydrotestosterone levels. The user wonders why this treatment is not widely discussed or if it has been discredited.

The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.